Why Is Neuromuscular Disease Focused Entrada Therapeutics Shares Trading Lower Today?
Entrada Therapeutics Inc TRDA shares are trading lower after the company announced updates on ENTR-601-44 in Duchenne Muscular Dystrophy. The FDA previously notified Entrada that the Investigational New Drug (IND) application for the Phase 1 clinical trial of ENTR-601-44 had been placed on…#fda #entrada #dipaldoshi #entradatherapeutics #williamblair
Source: Reuters: Health - Category: Consumer Health News Source Type: news
More News: Brain | Clinical Trials | Health | Investigational New Drugs | Muscular Dystrophy | Neurology | Reflex Sympathetic Dystrophy